Apparently Nonspecific Enzyme Elevations After Portal Vein Delivery of Recombinant Adeno-Associated Virus Serotype 2 Vector in Hepatitis C Virus-Infected Chimpanzees
- 1 July 2008
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 19 (7) , 681-689
Abstract
Hepatic gene transfer is envisioned as a substitute for protein replacement therapies, many of which are derived from blood products. Thus, the target populations may have a high prevalence of blood-borne pathogens, such as hepatitis C virus (HCV). We sought to determine whether the safety of recombinant adeno-associated virus serotype 2 (rAAV2) would be altered by preexisting HCV infection. Doses of approximately 1 × 1013 vector genomes of an rAAV2-chimpanzee α1-antitrypsin (rAAV2-cAAT) vector were injected into the portal vein of each of three HCV genome-positive (HCV+) chimpanzees and three HCV-negative (HCV−) controls. Acute safety studies were performed up to 90 days after vector administration, along with analyses of the peripheral blood and liver tissue for rAAV2-cAAT genomes. Vector genome copy numbers in blood and liver tissue were similar in both groups. All animals demonstrated increases in liver and muscle enzyme levels after the pretreatment liver biopsy (5 days before vector injection) and after the vector injection. However, HCV+ animals demonstrated a substantially greater rise in aspartate aminotransferase, alanine aminotransferase, and creatinine phosphokinase values than HCV− animals. Histopathology demonstrated abnormal lipid accumulation (steatosis) in the hepatocytes of HCV+ animals, both before and after vector injection. These data indicate an increased susceptibility to subclinical liver toxicity from portal vein injection of rAAV2 in the presence of HCV infection.Keywords
This publication has 26 references indexed in Scilit:
- Phase I Trial of Intramuscular Injection of a Recombinant Adeno-Associated Virus Serotype 2 α 1-Antitrypsin (AAT) Vector in AAT-Deficient AdultsHuman Gene Therapy, 2006
- Correlation Between DNA Transfer and Cystic Fibrosis Airway Epithelial Cell Correction After Recombinant Adeno-Associated Virus Serotype 2 Gene TherapyHuman Gene Therapy, 2005
- Long-Term Persistence of Infection in Chimpanzees Inoculated with an Infectious Hepatitis C Virus Clone Is Associated with a Decrease in the Viral Amino Acid Substitution Rate and Low Levels of HeterogeneityJournal of Virology, 2004
- Immune Responses to Recombinant Adeno-Associated Virus Vectors: Putting Preclinical Findings into PerspectiveHuman Gene Therapy, 2004
- A critical role for the chimpanzee model in the study of hepatitis C†Hepatology, 2004
- Clinical Gene Transfer Studies for Hemophilia BSeminars in Thrombosis and Hemostasis, 2004
- Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectorsGene Therapy, 2001
- Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectorsGene Therapy, 2001
- CMV-β-Actin Promoter Directs Higher Expression from an Adeno-Associated Viral Vector in the Liver than the Cytomegalovirus or Elongation Factor 1α Promoter and Results in Therapeutic Levels of Human Factor X in MiceHuman Gene Therapy, 2001
- A Phase I/II Study of tgAAV-CF for the Treatment of Chronic Sinusitis in Patients with Cystic Fibrosis. Stanford University, Stanford, CaliforniaHuman Gene Therapy, 1998